. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007 Sep;13(9):1029-31. PubMed.


Please login to recommend the paper.


  1. Sagare et al. report for the first time, the ability of systemically administered Aß-binding, recombinant soluble LRP cluster IV (sLRP-IV) to lower cerebral Aß levels and increase peripheral Aß in plasma. This provides proof-of-concept that sLRP-IV may have therapeutic potential for the prevention and, possibly, the treatment of AD.

    The authors suggest that sLRP-IV has potential as a systemic Aß-lowering therapy by virtue of its ability to enhance cerebral blow flow, enhance efflux of Aß from brain to blood, and prevent re-uptake of Aß from blood to brain. As a result, and based on their APP tg mouse studies, they predict that such a treatment will prevent or reduce Aß deposition in brain, thereby staving off plaque-associated changes such as gliosis and neuritic dystrophy and preventing learning and memory deficits.

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Enhancing Peripheral Sink Scours Brain of Amyloid
  2. Vassar, Wolfe, Zlokovic Win 2009 Potamkin Prize